 |
The European Medicines Agency, an advisory body for drug regulators in Europe, recommended last week that the warning label for the multiple sclerosis drug Tysabri be updated.
This is following new reports of users developing a rare brain disease known as PML, or progressive multifocal leukoencephalopathy.
Source: European Medicines Agency
Weblink: click here
|
